Labcorp Appoints Victor Bulto to Board of Directors
Labcorp (NYSE: LH) announced the appointment of Victor Bulto to its Board of Directors, effective December 1, 2025. Bulto currently leads Novartis' U.S. business, a $20+ billion operation, and brings 25 years of global healthcare leadership across oncology, immunology, neuroscience, and cardiovascular-renal-metabolic areas.
Labcorp highlighted his experience in transformation, technology and automation, and commercial strategy as supportive of its long-term growth priorities in precision medicine, patient access to novel therapies, and innovation through science and technology.
Labcorp (NYSE: LH) ha annunciato la nomina di Victor Bulto nel consiglio di amministrazione, con effetto dal 1 dicembre 2025. Bulto attualmente guida l'attività statunitense di Novartis, un'operazione da oltre 20 miliardi di dollari, e porta con sé 25 anni di leadership globale nel settore sanitario, nei campi dell'oncologia, immunologia, neuroscienze e cardiovascolare-renale-metabolico.
Labcorp ha evidenziato la sua esperienza in trasformazione, tecnologia e automazione, nonché in strategia commerciale come elementi di supporto alle sue priorità di crescita a lungo termine nella medicina di precisione, nell'accesso dei pazienti a terapie innovative e nell'innovazione tramite scienza e tecnologia.
Labcorp (NYSE: LH) anunció la incorporación de Victor Bulto a su Junta Directiva, con efecto a partir de 1 de diciembre de 2025. Bulto dirige actualmente el negocio de EE. UU. de Novartis, una operación de más de 20.000 millones de dólares, y aporta 25 años de liderazgo global en salud en las áreas de oncología, inmunología, neurociencias y cardiovascular-riñal-metabólica.
Labcorp destacó su experiencia en transformación, tecnología y automatización, y en estrategia comercial, como factores que respaldan sus prioridades de crecimiento a largo plazo en medicina de precisión, acceso de los pacientes a terapias innovadoras y la innovación a través de la ciencia y la tecnología.
Labcorp (NYSE: LH)는 이사회에 Victor Bulto를 임명했고, 효력을 발휘하는 시점은 2025년 12월 1일입니다. Bulto는 현재 노바티스의 미국 사업을 이끌고 있으며, 200억 달러를 넘는 규모의 운영을 담당하고 있으며, 종양학, 면역학, 신경과학, 심혈관-신장-대사 영역에서 25년의 글로벌 보건의료 리더십을 보유하고 있습니다.
Labcorp는 변혁, 기술 및 자동화, 상업 전략에 대한 그의 경험이 정밀의료, 환자 접근성, 과학 및 기술을 통한 혁신이라는 장기 성장 우선 순위를 지지한다고 강조했습니다.
Labcorp (NYSE : LH) a annoncé la nomination de Victor Bulto au conseil d'administration, avec effet à partir du 1er décembre 2025. Bulto dirige actuellement l'activité américaine de Novartis, une opération de plus de 20 milliards de dollars, et apporte 25 ans de leadership mondial dans le domaine des soins de santé, couvrant l'oncologie, l'immunologie, les neurosciences et les domaines cardiovasculaire-rénal-métabolique.
Labcorp a souligné son expérience en transformation, technologie et automatisation, ainsi que sa stratégie commerciale, comme des facteurs soutenant ses priorités de croissance à long terme dans la médecine de précision, l'accès des patients à des thérapies novatrices et l'innovation par la science et la technologie.
Labcorp (NYSE: LH) gab die Berufung von Victor Bulto in das Board of Directors bekannt, wirksam ab 1. Dezember 2025. Bulto leitet derzeit das US-Geschäft von Novartis, eine über 20 Milliarden Dollar schwere Operation, und bringt 25 Jahre globale Führung im Gesundheitswesen in Bereichen wie Onkologie, Immunologie, Neurowissenschaften sowie kardiovaskulär-renale-metabolische Bereiche mit.
Labcorp hob seine Erfahrungen in Transformation, Technologie und Automatisierung sowie in der kommerziellen Strategie hervor, die seine langfristigen Wachstumsprioritäten in Präzisionsmedizin, Patientenzugang zu innovativen Therapien und Innovation durch Wissenschaft und Technologie unterstützen.
Labcorp (NYSE: LH) أعلن عن تعيين فيكتور بولتو في مجلس الإدارة، اعتباراً من 1 ديسمبر 2025. بولتو يقود حالياً نشاط الولايات المتحدة لدى نوفارتس، وهو عملية تبلغ قيمتها أكثر من 20 مليار دولار، ويجلب 25 عاماً من القيادة العالمية في الرعاية الصحية عبر مجالات الأورام، المناعة، علم الأعصاب، والقلب-الكلى-الاستقلاب.
وأبرزت Labcorp خبرته في التحول والتكنولوجيا والأتمتة والاستراتيجية التجارية كعناصر تدعم أولوياتها للنمو على المدى الطويل في الطب الدقيق، وصول المرضى إلى علاجات مبتكرة، والابتكار من خلال العلم والتكنولوجيا.
- None.
- None.
Bulto, President,
BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025.
Bulto is an accomplished global executive with 25 years of experience in healthcare, and a proven track record of leading large, complex organizations across the
"Victor's appointment to our Board underscores Labcorp's focus on long-term growth through innovation and global healthcare leadership," said Adam Schechter, Chairman and Chief Executive Officer of Labcorp. "His experience leading one of the largest pharmaceutical businesses in the
"I deeply believe in Labcorp's mission and am honored to join the Board at a time of industry growth and medical advancement, particularly in the field of precision medicine," said Bulto. "Labcorp's scale and infrastructure, combined with its commitment to meaningful patient impact, create a unique opportunity to accelerate access to novel therapies and shape the future of healthcare."
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-appoints-victor-bulto-to-board-of-directors-302623576.html
SOURCE Labcorp Holdings Inc
FAQ
Who is Victor Bulto and when does he join Labcorp's board (LH)?
What experience does Victor Bulto bring to Labcorp (NYSE: LH)?
How might Victor Bulto's appointment affect Labcorp's strategy (LH)?
What areas of expertise does Victor Bulto have relevant to Labcorp (LH)?
Who commented on Victor Bulto's appointment to Labcorp's board (LH)?
Will Victor Bulto's board role at Labcorp (LH) change his position at Novartis?
